Bayer (FRA:BAYN) has been assigned a €95.00 ($110.47) target price by research analysts at Credit Suisse Group in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Credit Suisse Group’s price target indicates a potential upside of 43.61% from the company’s current price.
A number of other equities research analysts have also issued reports on the stock. Deutsche Bank set a €127.00 ($147.67) price objective on shares of Bayer and gave the company a “buy” rating in a report on Thursday. Commerzbank set a €111.00 ($129.07) target price on Bayer and gave the company a “buy” rating in a research report on Wednesday. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the company a “buy” rating in a research report on Wednesday. UBS Group set a €122.00 ($141.86) target price on Bayer and gave the company a “buy” rating in a research report on Tuesday, October 23rd. Finally, equinet set a €96.00 ($111.63) target price on Bayer and gave the company a “buy” rating in a research report on Tuesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of €97.50 ($113.37).
Shares of BAYN opened at €66.15 ($76.92) on Friday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: How Short Selling Works
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.